3-phenyl-1-{[1-(phenylthio)cyclopropyl]carbonyl}piperidine | 872992-42-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 3-phenyl-1-{[1-(phenylthio)cyclopropyl]carbonyl}piperidine
• 英文别名: Piperidine, 3-phenyl-1-[[1-(phenylthio)cyclopropyl]carbonyl]-；(3-phenylpiperidin-1-yl)-(1-phenylsulfanylcyclopropyl)methanone
• CAS: 872992-42-2
• 化学式: C₂₁H₂₃NOS
• 分子量: 337.486
• InChiKey: OZFIQFOWJRHRJW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  45.6
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Amido compounds and their use as pharmaceuticals
  申请人：Yao Wenqing

  公开号：US20060009491A1

  公开（公告）日：2006-01-12

  The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.

  本发明涉及11-β羟基类固醇脱氢酶1型的抑制剂、矿物质皮质激素受体（MR）的拮抗剂及其制药组合物。本发明的化合物可用于治疗与11-β羟基类固醇脱氢酶1型的表达或活性相关的各种疾病和/或与醛固酮过多相关的疾病。
• Pharmaceutical composition, comprising a steroid-dehydrogenase-reductase inhibitor, and a mineralocorticoid receptor antagonist.
  申请人：OntoChem GmbH

  公开号：EP2243494A1

  公开（公告）日：2010-10-27

  A treatment using a hydroxysteroid dehydrogenase reductase inhibitor combined with a mineralocorticoid receptor antagonist is provided which overcomes the problem that manipulating cortisol levels by a single compound therapy induces other pathologies or side effects, while the original condition that required treatment is ameliorated.

  提供了一种使用羟基类固醇脱氢酶还原酶抑制剂与矿物皮质激素受体拮抗剂相结合的治疗方法，该方法克服了通过单一化合物疗法控制皮质醇水平会诱发其他病症或副作用的问题，而需要治疗的原有病症却得到了改善。
• AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS
  申请人：INCYTE CORPORATION

  公开号：EP1773773A1

  公开（公告）日：2007-04-18
• EP1773773A4
  申请人：——

  公开号：EP1773773A4

  公开（公告）日：2009-07-29
• [EN] AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS<br/>[FR] COMPOSES AMIDO ET LEUR UTILISATION EN TANT QUE PRODUITS PHARMACEUTIQUES
  申请人：INCYTE CORP

  公开号：WO2006002350A1

  公开（公告）日：2006-01-05

  The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression of activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.